Oncolys to Receive 500 Million Yen from Chugai in Telomelysin Milestone

December 13, 2019
Oncolys BioPharma said on December 12 that it will receive a milestone payment of 500 million yen from Chugai Pharmaceutical as pre-set criteria were met in ongoing clinical trials for its oncolytic viral immunotherapy telomelysin. This is the first time...read more